Over the past decade, various enzyme/prodrug systems such as thymidine kinase/ganciclovir (TK/ GCV), yeast cytosine deaminase/5-fluorocytosine (yCD/5-FC) and nitroreductase/CB1954 (NTR/ CB1954) have been used for stem cell mediated suicide gene therapy of cancer. Yet, no study has been conducted to compare and demonstrate the advantages and disadvantages of using one system over another. Knowing that each enzyme/prodrug system has its own strengths and weaknesses, we utilized mesenchymal stem cells (MSCs) as a medium to perform for the first time a comparative study that illustrated the impact of subtle differences among these systems on the therapeutic outcome. For therapeutic purposes, we first genetically modified MSCs to stably express a panel of four suicide genes including TK (TK 007 and TK SR39 mutants), yeast cytosine deaminase: uracil phosphoribosyltransferase (yCD:UPRT) and nitroreductase (NTR). Then, we evaluated the anticancer efficacies of the genetically engineered MSCs in vitro and in vivo by using SKOV3 cell line which is sensitive to all four enzyme/prodrug systems. In addition, all MSCs were engineered to stably express luciferase gene making them suitable for quantitative imaging and dose-response relationship studies in animals. Considering the limitations imposed by the prodrugs' bystander effects, our findings show that yCD:UPRT/5-FC is the most effective enzyme/prodrug system among the ones tested. Our findings also demonstrate that theranostic MSCs are a reliable medium for the side-by-side evaluation and screening of the enzyme/prodrug systems at the preclinical level. The results of this study could help scientists who utilize cellbased, non-viral or viral vectors for suicide gene therapy of cancer make more informed decisions when choosing enzyme/prodrug systems.
Introduction
Stem cell mediated gene delivery is emerging as a new strategy to improve the safety and efficacy of current cancer gene therapy methods. Recent evidence indicates that systemically administered mesencymal stem cells (MSCs) can migrate and deliver therapeutic genes to tumors [1] [2] [3] . It is envisioned that this inherent tumor tropism of MSCs can be exploited to develop effective and well-tolerated treatments for patients with malignant solid tumors [4, 5] . For this purpose, MSCs are first genetically modified ex-vivo to stably express a prodrug-converting enzyme (e.g., thymidine kinase, cytosine deaminase, nitroreductase, etc.) and then injected back into the body to migrate into tumors. Subsequently, a prodrug is administered which gets converted into its cytotoxic form by the enzyme inside the MSCs. This in turn results in the death of the stem cells as well as neighboring cancer cells through a phenomenon known as "bystander effect" [6] [7] [8] . Therefore, in addition to the number of MSCs that reach the tumor target, prodrug's bystander effect also plays a major role in the success of this approach. Although in the past decade several different enzyme/prodrug systems are utilized for this purpose, literature search shows that thymidine kinase/ ganciclovir (TK/GCV) and yeast cytosine deaminase/5-fluorocytosine (yCD/5-FC) are the most widely used systems [9] [10] [11] [12] . Unfortunately, in many cases no clear rationale is provided to justify the use of one enzyme/prodrug system over another and it has been unclear which enzyme/prodrug system is the most effective one. As we have discussed elsewhere and knowing that each enzyme/prodrug system has its own strengths and weaknesses [13] , it is important to be able to perform a study at the preclinical level that can reliably illustrate the strengths and weaknesses of using different enzyme/prodrug systems and/or compare the efficacies of different enzyme mutants.
The overall objective of this research was to genetically engineer a panel of MSCs that stably express TK (TK 007 and TK SR39 mutants), yCD:UPRT and nitroreductase (NTR) suicide genes and evaluate their anticancer efficacies side-by-side by using a sensitive tumor model. To achieve the objective, we genetically modified bone-marrow derived MSCs to stably express the aforementioned suicide genes and evaluated their ability to kill xenografts of SKOV3 ovarian cancer tumors after administration of an appropriate prodrug. This model cancer cell line was chosen because of its sensitivity to the enzyme/prodrugs systems used in this study [14] [15] [16] . The use of a cancer cell line that is sensitive to the enzyme/prodrug systems is essential as it helps to eliminate the cell-related bias. As a result, the observed differences in terms of therapeutic outcome will not be due to the cell's biological traits but the enzyme/prodrug systems' properties. Therefore, cell lines that are not sensitive (resistant) to one system or another will not be suitable for such comparative studies.
TK 007 and TK SR39 are the most efficient mutants of wild-type TK with the ability to rapidly convert GCV into its cytotoxic form inside the TK expressing cells [17, 18] . Bacterial nitroreductase (NTR) is able to convert CB1954 prodrug into its potent cytotoxic form [19, 20] . In comparison to yCD alone, yCD:UPRT, which is a combination of yCD and UPRT, has a higher sensitivity to 5-FC. Therefore, yCD:UPRT can convert this prodrug into its cytotoxic form in a faster rate resulting in higher efficacy [21, 22] . Using an in vitro cell toxicity assay, we first examined the sensitivity of the suicide gene expressing MSCs to prodrugs followed by studying their ability to kill SKOV3 cancer cells through their bystander effects. From the in vitro studies, three of the most efficient suicide gene expressing MSCs were selected and then used to evaluate their ability in killing SKOV3 xenograft tumors in nude mice. To correlate dose with response, all MSCs were engineered to stably express luciferase gene and the in vivo viability of MSCs were tracked and monitored before and after prodrug administration.
Materials and Methods

Genetic engineering of suicide gene expressing MSCs
All the recombinant DNA work presented here has been reviewed and approved by the Rutgers University Environmental Health and Safety office. The genes encoding yCD:UPRT and wild-type herpes simplex virus thymidine kinase (HSVTK) were purchased from Invivogen (San Diego, CA). Using site-directed mutagenesis wild-type HSVTK was mutated into TK SR39 as previously reported [17] . The full length NTR gene based on previously published data was synthesized by IDTDNA technologies (Coralville, IA) [19] . The gene encoding TK 007 enzyme was obtained from Professor B. Fehse (University Medical Centre Hamburg-Eppendorf, Germany) through Material Transfer Agreement. Using pBudCE4.1 dual promoter mammalian expression vector (Invitrogen), all suicide genes were cloned separately under EF1α promoter, whereas a firefly luciferase-GFP fusion gene was cloned under CMV promoter to facilitate colony selection and in vivo imaging. The sequences of all genes and fidelity to the original design were verified by DNA sequencing.
In the next step, human bone-marrow derived MSCs were first seeded in 58 cm 2 culture dishes at 3000-6000 cells/cm 2 density and propagated in DMEM media supplemented with 10% fetal bovine serum, 10,000 units/ml of penicillin and 10,000 μg/ml of streptomycin (Caisson, UT, USA). These cells were originally purchased from the Texas A&M Health Science Center College of Medicine and a generous gift from Professor P. Moghe at Rutgers University to our lab. MSCs were then transfected with the constructed mammalian expression vectors by using GeneIn™ reagent (GlobalStem®, MD, USA) to make MSC-TK 007 -Luc, MSC-TK SR39 -Luc, MSC-yCD:UPRT-Luc, and MSC-NTR-Luc. Transfected MSCs were maintained in full media and treated with 150 μl/ml Zeocin (Invitrogen, NY, USA) for 3-4 weeks to eliminate the nontransfected cells. Several colonies from each plate were picked and then propagated for further analysis.
In vitro and in vivo analysis of luciferase expression in genetically modified MSCs
The levels and stable expression of luciferase in all colonies were first evaluated in vitro by using luciferase assay kit and protocol (Promega). MSC-TK 007 -Luc, MSC-TK SR39 -Luc, MSC-yCD:UPRT-Luc and MSC-NTR-Luc were seeded separately in 96 well plates at the density of 2×10 4 cells per well. After 24 h the media were removed, cells were washed with Dulbecco's Phosphate Buffer Saline (DPBS) and 20 μl of lysis buffer was added to each well. Equal amounts of lysate were mixed with 50 μl of D-luciferin (Promega, WI, USA) in glass tubes and luminescence was measured by a luminometer (Berthold, Germany). Colonies with statistically similar luciferase expression were selected and propagated for in vivo evaluation.
The minimum number of genetically modified MSCs that can be detected in mice by IVIS imaging system (PerkinElmer, Waltham, MA, USA) after subcutaneous (SC) injection was examined by using MSC-TK SR39 clone. This was done by first suspending different number of cells ranging from 5×10 3 to 1×10 6 in 100 μl of DPBS:Matrigel (Corning, MA, USA) (50:50 v/v) and injecting it subcutaneously (SC) in the dorsal regions of female nude mice. D-luciferin (Goldbio®, St. Louis, MO, USA) was then injected intraperitoneally (IP) into the mice at the dose of 150 mg/kg. Five minutes after D-luciferin injection, mice were anesthetized by isoflurane inhalation and placed in IVIS imaging system to detect the cells. The in vivo bioluminescent images were displayed in "photon" mode; therefore, the signal intensity is represented by radiance (p/sec/cm2/sr), which refers to the number of photons per second that are leaving a square centimeter of tissue and radiating into a solid angle of one steradian (sr).
Evaluation of the sensitivity of suicide gene expressing MSCs to prodrugs
To study the expression and sensitivity of the suicide gene expressing MSCs to prodrugs, they were first seeded in 96-well plates at the density of 1×10 4 cells per well. The next day, the corresponding prodrug for each suicide gene expressing MSC; i.e., 5-FC for MSCyCD:UPRT-Luc; CB1954 for MSC-NTR-Luc; and GCV for MSC-TK 007 -Luc and MSC-TK SR39 -Luc were added to each well. 5-FC (PureChems TM , TX, USA), CB1954 (Medkoo Biosciences, NC, USA) and GCV (PureChems TM , TX, USA) prodrugs were added and incubated with the cells for 5 days in the following ranges: 0.1-1.5 μM, 10-200 μM and 0.1-5.0 μM, respectively. Cell viability was evaluated by WST-1 assay (Roche, Nutley, NJ) after addition of the reagent and measuring the absorbance at 450 nm. The viability of untransfected MSCs (naïve) treated with prodrug was used as control. The data are reported as mean±SD (n=3).
Evaluation of MSC tropism towards cancer cells by migration assay
The tropism of genetically modified MSCs towards cancer cells was studied by using migration assay. SKOV3 ovarian cancer cells and HEK 293 human embryonic kidney cells (control) were seeded in 24-well plates at the density of 1×10 5 cells per well. After 24 hours, inserts of 8-μm pore size (Greiner bio-one, NC, USA) were placed on the wells followed by transferring 2×10 4 genetically modified MSCs to each insert. After 48 hours, the inserts were taken out for staining and visualization. Briefly, cells inside each insert were removed with a cotton tip and the inserts were soaked in cold methanol for 10-20 min to fix the cells on the outer layer. The membrane was carefully cut off after washing with PBS and placed on a slide with the bottom side up. DAPI solution (Southern Biotech, Alabama, USA) was added onto the membranes to stain cells' nucleus. The cells were then visualized using a fluorescent microscope (Olympus, USA). The number of migrated cells was measured by counting five random fields of view per well under the microscope (ocular lens 10x, objective 10x, field of view 220 μm). The data are reported as mean±SD (n=5).
In vitro evaluation of the cancer cell killing efficiency of suicide gene expressing MSCs
Using a previously published method, we evaluated the ability of the suicide gene expressing MSC clones to kill SKOV3 cancer cells through the bystander effect [4, 5] . In brief, SKOV3 cells (doubling time: ~35 hours) were seeded in 96-well plates either alone or mixed with suicide gene expressing MSCs (doubling time: ~40 hours) at the density of 5×10 3 cells per well to generate MSC to SKOV3 ratios of 0:100 (SKOV3 alone), 1:50, 1:10, 1:5, and 1:2. The next day, the corresponding prodrugs at the concentrations of 50, 100 or 200 μM for each suicide gene were added to the wells. WST-1 assay was performed after 5 days to measure the cell viability. The absorbance of each MSC to SKOV3 co-culture without any prodrug treatment was considered as 100% viable. The data are reported as mean±SD (n=3).
In vivo evaluation of the tumor killing efficiency of the suicide gene expressing MSCs
Five-week old female nude mice were purchased from Jackson laboratory (Bar Harbor, ME) and used for the in vivo studies. All animals were cared for in accordance with the Rutgers Institutional Animal Care and Use Committee approved protocols. Mice were anesthetized by isoflurane inhalation and 3×10 6 SKOV3 cells suspended in 100 μl DPBS (50% Matrigel®) were injected SC in dorsal flank regions (two tumors per mouse). The tumor size growth was monitored by pressure sensitive caliper and when reached 100-150 mm 3 all mice were randomly distributed into 10 groups each containing 5 mice. First treatment group received intratumoral injection of 1×10 6 MSC-TK SR39 -Luc cells once a week plus daily injection of GCV (25 mg/kg). Second treatment group received intratumoral injection of 1×10 6 MSC-yCD:UPRT-Luc cells once a week plus daily injection of 5-FC (600 mg/kg). Third treatment group received intratumoral injection of 1×10 6 MSC-NTR-Luc cells once a week plus daily injection of CB1954 (20 mg/kg). Cell control groups received intratumoral injection of 1×10 6 MSC-TK SR39 -Luc, MSC-yCD:UPRT-Luc and MSC-NTR-Luc once a week, respectively (without prodrug). Prodrug control groups received daily injections of GCV (25 mg/kg), 5-FC (600 mg/kg) and CB1954 (20 mg/kg), respectively. Vehicle control group received intra-tumoral injection of PBS once a week. Genetically modified MSCs were administered intratumorally on days 0, 6, 12, 18, 24 and 30 (6 doses). Before each cell injection, tumor sizes and body weights were measured, D-luciferin injected (150 mg/Kg) and mice were imaged by IVIS imaging system. Five minutes after each cell injection, animals were imaged again to determine the total luciferase expression from the viable MSCs. In each weekly cycle, the prodrugs were administered one day post cell injection, continued for six days and stopped on the day of cell injection before the next cycle. The data are reported as mean±SD (n=10).
Results and Discussion
Intrinsic tumor tropism of stem cells has provided this opportunity for scientists to use them as a tool for delivery of various anticancer agents into the tumor environment [23] [24] [25] . There are two important factors that play significant roles in determining the success of stem cell mediated suicide gene therapy. One is the number of viable MSCs that come in contact with the tumor cells and the other is the potency of the drug's bystander effect. Similar to viral and non-viral vectors which get trapped in non-tumor tissues such as liver, a significant portion of the MSCs gets trapped in lungs after IV administration and only a subpopulation of them can reach the tumors [26, 27] . Therefore, the drug's bystander effect becomes the most prominent factor that could determine the rate of success. To compare the efficiency of the four enzyme/prodrug systems in stem cell mediated suicide gene therapy of cancer, we used a dual promoter mammalian expression vector. This was done by cloning four different suicide genes separately (i.e., TK 007 , TK SR39 , yCD:UPRT and NTR) under an EF1α promoter and a luciferase gene under CMV promoter. The fidelity of the each sequence to the original design was verified by DNA sequencing and translation into the corresponding amino acid sequence (Supplementary Figures S1 and S2) . The plasmids were then used to create stably transfected MSC-TK 007 -Luc, MSC-TK SR39 -Luc, MSC-yCD:UPRT-Luc and MSC-NTR-Luc clones suitable for simultaneous therapy and quantitative in vivo imaging. In the next step, we determined the expression of luciferase protein in all four stably transfected clones and selected those with statistically similar luciferase expression levels. As it can be observed in Figure 1A , all four selected clones could express luciferase gene at statistically similar levels (ANOVA, p>0.05). To examine whether this level of luciferase expression is high enough to be detected in nude mice, one clone was selected (i.e., MSC-TK SR39 -Luc) and various numbers of MSCs were injected subcutaneously. The results showed that the expression of luciferase was sufficient to allow us detect as low as 5,000 MSCs and there was a good correlation between the cell number and Radiance ( Figure 1B and C). The ability to detect MSCs in vivo with high degree of sensitivity is important because it makes it possible to perform more accurate dose-response relationship studies.
We then examined the sensitivity of the genetically modified MSCs to prodrugs using a cell toxicity assay. This was to verify that the engineered MSCs could express suicide genes at levels sufficiently high that could induce significant cell death in the presence of the corresponding prodrug. The results of this study showed that all four suicide gene expressing MSC clones were sensitive to prodrugs in a dose-dependent manner while naïve MSCs remained insensitive ( Figure 2) . Among all MSC clones, it was apparent that the MSC-yCD:UPRT-Luc was the most sensitive one (5-FC IC 50 0.2 μM). In addition, we did not observe any significant difference between MSC-TK 007 -Luc and MSC-TK SR39 -Luc clones in terms of sensitivity to GCV (IC 50 ~0.5 μM). Overall, the results of the cytotoxicity study show that all four genetically modified MSCs were able to convert prodrugs into their cytotoxic forms which resulted in the death of suicide gene expressing MSCs. Although in many cases it may be desirable to see MSCs die as a result of prodrug conversion but it is worth noting that in some cases it may even be advantageous for the MSCs not to die and remain active so that they can produce more cytotoxic drugs in the tumor environment.
Learning that all the genetically modified MSC clones could efficiently express not only the luciferase gene but also the suicide genes, we utilized a migration assay to examine whether the genetic manipulation of MSCs affected their inherent tropism towards cancer cells. Thus, we studied the tropism of MSCs towards SKOV3 cancer cells and compared it with tropism towards HEK293 normal cells. The results of this assay demonstrated that all genetically modified MSC clones maintained their cancer tropism by migrating at significantly higher numbers towards cancer cells in comparison to HEK293 cells (t-test, p<0.05) ( Figure 3) . Based on published data by other groups, this observation was expected [28] .
Next, we examined whether the prodrugs after conversion into their cytotoxic form inside the MSCs can diffuse out and kill neighboring cancer cells (bystander effect). For this purpose, we separately co-cultured each suicide gene expressing MSC clone with SKOV3 ovarian cancer cells at different MSC to cancer cell ratios followed by administration of prodrugs. The results of this study illustrated that all genetically modified MSCs could significantly induce cell death in SKOV3 cancer cells ( Figure 4A-D) .
More specifically, we did not observe any significant increase in cancer cell killing efficiency by MSC-TK SR39 -Luc, MSC-TK 007 -Luc and MSC-yCD:UPRT-Luc clones when prodrug concentration increased from 50 μM to 200 μM. This could be due to the fact that the IC 50 of GCV and 5-FC for all these clones as shown in Figure 2 were less than 1 μM. In contrast, MSCNTR-Luc clone showed dose dependent cancer cell killing efficiency with maximum efficacy at 200 μM of prodrug. This observation correlates very well with the results in Figure 2 which showed more than 100 μM of CB1954 is needed to kill at least 70% of MSC-NTR-Luc cells. To evaluate the potency of the bystander effect with these enzyme/prodrug systems, we used the data in Figure 4 and plotted the best curve fit for all four clones when exposed to 200 μM of prodrug. Comparison of the slopes of the lines and statistical analysis of data revealed the following order of the bystander effect: TK SR39 =TK 007 >NTR>yCD:UPRT (ANOVA followed by posthoc Tukey test, p<0.05) ( Figure 5 ). The similarity of sensitivity to prodrug and bystander effects for MSC-TK SR39 -Luc and MSC-TK 007 -Luc clones signifies that both suicide genes could effectively convert GCV into its charged cytotoxic form GCV-triphosphate (GCV-TP). Moreover, it indirectly suggests that gap junctions were present in between MSCs and SKOV3 cells because the bystander effect induced by GCV-TP is largely dependent on active transport via gap junctional intercellular communication (GJIC) [29] . In a mechanistic study by , the formation of gap junctions between MSCs and cancer cells after co-culturing is demonstrated [6] .
As we mentioned in the introduction section, in previous published studies with suicide gene expressing MSCs no clear rationale is provided to justify the use of one enzyme/prodrug system over another. The data in Figure 5 which shows the high anticancer activity of TK/GCV system provides the rationale for using this system to effectively kill cancer cells at least at the in vitro level. However, this observation does not explain why the only ongoing two MSC mediated suicide gene therapy protocols in the clinic are based on CD/5-FC system and not TK/GCV or NTR/CB1954. Therefore, we continued the evaluation of these systems at the in vivo level to get a better understanding of the limiting factors.
Based on these results which showed no significant difference between MSC-TK SR39 -Luc and MSC-TK 007 -Luc clones, we selected MSC-TK SR39 -Luc as a candidate along with MSCNTR-Luc for the in vivo studies. Although MSC-yCD:UPRT-Luc clone showed lower levels of anticancer efficacy in comparison to others, but we decided to evaluate its in vivo efficacy since its bystander effect is not GJIC dependent. Therefore, MSC-TK SR39 -Luc, MSC-NTR-Luc and MSC-yCD:UPRT-Luc were propagated and used to evaluate their efficacy in killing SKOV3 tumors in nude mice.
Besides the prodrug's bystander effect the number of MSCs that come in contact with tumor cells plays a crucial role in determining the therapeutic outcome of the MSC mediated suicide gene therapy [26] . Therefore, we had to choose the most appropriate route of administration to ensure that all tumors receive equal number of MSCs. It has been shown that after each systemic administration a significant number of MSCs get cleared by pulmonary first pass effect [27] . In addition to pulmonary clearance, other factors such as tumor type and stem cell lineage and size could also impact the number of stem cells that reach tumors [30] . Therefore, to eliminate the impact of stem cell lineage/size and pulmonary first pass effect on the number of MSCs that reach tumors we injected all MSC clones intratumorally. This ensures that all tumors receive consistent and known number of MSCs. Since our data in Figure 3 show that all the genetically modified MSCs maintained their cancer tropism, therefore it is highly likely that the MSCs after intratumoral injection remain in the tumor vicinity. To validate the delivery of viable MSCs to the tumors, all mice were imaged and luciferase expression quantified immediately after receiving one million MSCs intratumorally. After treatment with prodrugs for six days, all mice were imaged again and luciferase expression quantified to examine whether the MSCs responded to prodrugs. As soon as the effect of prodrug on MSC viability was measured, the next doses of viable MSCs were injected. For each treatment group (MSC plus prodrug) we used the corresponding cell treated group (no prodrug) as a control. This was to evaluate whether MSCs can remain alive in mice and confirm that the decrease in bioluminescent signal is due to prodrug treatment and not other factors such as clearance by the mice natural killer cells. Qualitative and quantitative analysis of the luciferase signal before and after treatment with prodrugs demonstrated that the GCV and 5-FC at the administered dose could significantly kill the MSCTK SR39 -Luc and MSC-yCD:UPRT-Luc clones, respectively ( Figure 6A and B) . However, the MSC-NTR-Luc was mildly responsive to the maximum tolerable dose of CB1954 and the luciferase signal did not change as significant as others before and after prodrug administration ( Figure 6C ). It is worth noting that the bioluminescent signal did not increase overtime in the group treated with MSC-NTR-Luc plus CB1954 suggesting that a portion of the MSCs were responding to prodrug treatment although it was not sufficient to cause dramatic change in signal strengths similar to other groups. Unfortunately, we could not exceed the 20 mg/Kg/day for CB1954 because at higher concentrations mice showed significant hepatotoxicity and started to lose weight. Dosedependent hepatotoxicity is one of the major side effects of CB1954 which has limited its use [31] .
It is well-documented that CB1954 is a potent DNA chelating agent which can freely diffuse to surrounding cells and trigger extensive DNA damage and P53-independent apoptosis in both replicating and non-replicating cells [32] . However, it has also been reported that the conversion rate of CB1954 by NTR is somewhat low as CB1954 is not the natural substrate of NTR [20] . Therefore, the fact that we didn't observe significant reduction in luciferase signal before and after treatment with CB1954 in MSC-NTR-Luc treated mice was explicable. As a result of this observation, we reduced the number of injected MSC-NTRLuc to 500,000 cells after day 12 because the majority of the injected MSC-NTR-Luc cells from previous dose were still alive. Nonetheless, we continued the treatment of all mice for 36 days until the size of tumors in control groups exceeded the 1000mm 3 limits. At this point, the tumor sizes were big enough to interfere with the mice natural movements causing distress. Therefore, mice were euthanized at this point and the study was stopped on day 36.
The tumor measurement studies during the period of treatment showed that in comparison to the control groups, mice treated with MSC-TK SR39 -Luc plus GCV or MSC-NTR-Luc plus CB1954 did not respond to therapy and the tumor size growth did not get affected significantly (Repeated measure analysis, p>0.05) ( Figure 7A and C) . Based on the data in Figure 6 , the lack of response to therapy with MSC-NTR-Luc plus CB1954 was expected since the conversion rate of CB1954 into its cytotoxic form was not high enough to induce significant MSC death. The fact that we did not observe any significant difference between groups treated with MSC-TK SR39 -Luc plus GCV or GCV alone indicates that significantly higher numbers of MSCs are required to come in contact and cause considerable damage to cancer cells in a fast growing tumor model. It appears that to slow down the growth of a tumor that has surpassed the 200mm 3 volume, administration of more than 1 million MSCs per week is necessary. This is sensible as the efficacy of GCV-TP is entirely dependent on GJIC and in tumors gap junctions in between cancer cells are either highly compromised or in many cases non-existent [29, 33] . Literature search also shows that TK/GCV enzyme/ prodrug therapy has been effective when tumors were small (<100mm 3 ) and treated early [34, 35] . Most importantly, these results could also explain why despite significant success at the preclinical level [6, 7, 36] , no MSC mediated suicide gene therapy protocol with TK/GCV system has reached the clinic. This is also consistent with the results of virusbased suicide gene therapy protocols with TK/GCV system which passed Phase I clinical trials (safety) but later failed at efficacy [13, 37] .
In contrast to TK/GCV system, mice that were treated with 1 million per week MSCyCD:UPRT-Luc plus daily administration of 5-FC responded well to therapy and the tumor growth could be inhibited significantly (Repeated measure analysis, *p<0.05) ( Figure 7B and D). This response could be attributed to two important factors; one is GJIC-independent diffusion of 5-FU which significantly enhances drug's bystander effect and the other is the efficiency of yCD:UPRT enzyme in converting 5-FC to 5-FU. Here, we administered one million MSCs to each tumor once a week which could inhibit tumor growth but not eradicate completely. It is worth mentioning that at low concentrations 5-FU has been shown to kill mostly dividing cancer cells; however, at high concentrations it could kill even non-dividing cancer cells through disruption of mRNA processing and protein synthesis [38] . Therefore, a combination of enzyme efficiency and prodrug's physicochemical properties has been responsible for effective killing of the tumor cells. To achieve complete tumor remission, either injection of higher doses of MSCs or use of other enzyme/prodrug systems with better bystander effect may be needed. The fact that the only MSC mediated suicide gene therapy protocols that have reached clinical trials are based on CD/5-FC system (NCT02015819 and NCT01172964), points at the potentially higher efficacy of this system over others and in line with our findings. Since there are several other enzyme/prodrug systems also available, use of theranostic MSCs for preclinical screening could be expanded to compare the anticancer efficacy of yCD:UPRT/5-FC with other potentially effective systems such as carboxylesterase/irinotecan. For preclinical screening, it is important to choose a cell line that is sensitive to all the enzyme/prodrug systems of interest so that the outcome is not biased. The sensitivity test as shown in Figures 4 and 5 ensures the chosen cell line is suitable for screening process and identification of a system that can cause maximum damage to cancer cells. Non-sensitive cell lines (resistant) can be used in cases where enzyme/prodrug systems are being screened to find one that can generate sufficiently high concentrations of activated prodrug to overcome resistance. For example, non-dividing breast cancer cells are shown to be resistant to therapy with low concentrations of 5-FU but responsive when the 5-FU concentration is high [38] . Therefore, various yCD mutants can be screened through use of theranostic MSCs as shown in this study to find one that can generate high concentrations of 5-FU and overcome resistance.
Conclusions
Success of stem cell mediated suicide gene therapy of cancer is dependent to a large extent on the conversion rate of the prodrug into its cytotoxic form and also the bystander effect. Among the enzyme/prodrug systems tested in this study, our quantitative imaging and tumor size measurement studies show that yCD:UPRT/5-FC is the most effective system. Our findings also show that before choosing an enzyme/prodrug system for cancer therapy, important factors such as prodrug's conversion rate and bystander effect and limitations imposed by tumor pathophysiology (e.g., absence of gap junctions) need to be carefully considered.
Since this study provides evidence that genetically modified MSCs can be used as a means for side-by-side evaluation of the efficacy of enzyme/prodrug systems, it may open the door to utilization of this approach for screening a large number of enzyme mutants or prodrugs with different levels of bystander effects at the preclinical level. Given that in the clinic the suicide gene expressing MSCs are going to be injected intravenously where a significant portion of the cells may be lost, such studies at the preclinical level would help identify the most effective enzyme/prodrug systems before moving into costly clinical trials. Regardless of vector types used (viral, non-viral or cell based), these findings could help scientists in the field of suicide gene therapy of cancer make more informed decisions when choosing enzyme/prodrug systems and effectively expand this field of study.
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